Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients With Advanced Prostate Cancer Treated With Apalutamide in the SPARTAN and TITAN Studies

Eric J. Small, Kim N. Chi, Simon Chowdhury, Katherine B. Bevans, Amitabha Bhaumik, Fred Saad, Byung Ha Chung, Lawrence I. Karsh, Stéphane Oudard, Peter De Porre, Sabine D. Brookman-May, Sharon A. McCarthy, Suneel D. Mundle, Hirotsugu Uemura, Matthew R. Smith, Neeraj Agarwal, on behalf of the SPARTAN and TITAN investigators

SUPPLEMENTAL TABLE 1: Baseline disease characteristics by PSA response at 3 months

	SPARTAN, nmCRPC				TITAN, mCSPC			
	APA		PBO		APA		PBO	
	With PSA reduction to ≤ 0.2 ng/mL	Without PSA reduction to ≤ 0.2 ng/mL	With PSA reduction to ≤ 0.2 ng/mL	Without PSA reduction to ≤ 0.2 ng/mL	With PSA reduction to ≤ 0.2 ng/mL	Without PSA reduction to ≤ 0.2 ng/mL	With PSA reduction to ≤ 0.2 ng/mL	Without PSA reduction to ≤ 0.2 ng/mL
Patients	119	380	0	214	127	121	53	188
Age, median yr	72	73	_	73	69	67	67	67
Time from initial diagnosis to randomization, median yr	6.8	8.7	_	8.2	3.8	3.4	5.5	3.2
Tumor stage at diagnosis, n (%)								
TO	0	0	_	0	1 (1)	0	0	0
T1	19 (16)	69 (18)	_	37 (18)	7 (6)	9 (7)	5 (9)	4 (2)
T2	44 (37)	125 (33)	_	59 (28)	33 (26)	35 (29)	11 (21)	41 (22)
T3	47 (40)	134 (36)	_	93 (45)	58 (46)	40 (33)	23 (43)	88 (47)
T4	6 (5)	14 (4)	_	7 (3)	15 (12)	24 (20)	11 (21)	32 (17)
TX	3 (3)	32 (9)	_	13 (6)	13 (10)	13 (11)	3 (6)	23 (12)
Lymph node stage at diagnosis, n (%)								
N0	83 (70)	258 (68)	_	151 (72)	54 (43)	40 (33)	26 (49)	72 (38)
N1	14 (12)	57 (15)	_	31 (15)	44 (35)	52 (43)	18 (34)	68 (36)
NX	22 (19)	63 (17)	_	28 (13)	29 (23)	29 (24)	9 (17)	48 (26)
PSA doubling time, median mo	4.6	4.3	_	4.9				
ECOG PS								
0	101 (85)	300 (79)	_	171 (80)	88 (69)	70 (58)	39 (74)	118 (63)
1	18 (15)	80 (21)	_	43 (20)	39 (31)	51 (42)	14 (26)	70 (37)
Baseline PSA, median ng/mL	4.4	9.8	_	6.5	1.9	17.6	0.1	5.1
Baseline testosterone, median nmol/L	0.9	0.8		0.8				
Extent of disease								
Bone					127 (100)	121 (100)	53 (100)	188 (100)
Bone only					81 (64)	48 (40)	37 (70)	98 (52)
Lymph node		Data not applicable for	r SPARTAN, as patients		33 (26)	65 (54)	13 (25)	74 (39)
Visceral		had no evidence of metastatic disease at			13 (10)	17 (14)	4 (8)	30 (16)
Soft tissue		baseline by conventional imaging			7 (6)	5 (4)	4 (8)	6 (3)
Disease volume								
					68 (54)	95 (79)	28 (53)	126 (67)
High volume Low volume					59 (47)	26 (22)	25 (47)	62 (33)



ACKNOWLEDGMENTS

The SPARTAN and TITAN studies and the present analysis were funded by Janssen Research & Development, LLC. Editorial assistance was provided by Gwendolyn Elphick, PhD, and Tamara Fink, PhD, of Parexel, and was funded by Janssen Global Services, LLC.

© 2022 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Genitourinary Cancers Symposium. All rights reserved.